Pathstone Family Office, LLC Tyme Technologies, Inc. Transaction History

Pathstone Family Office, LLC

$15.6 Billion
Q3 2023

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Oct 23, 2023	BUY	$0.23 - $0.35 $115,025 - $175,038	500,109 New	500,109 $140,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $14,000 - $34,000	50,000 Added 11.11%	500,109 $175,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $162,289 - $281,301	270,482 Added 150.58%	450,109 $272,000
Q3 2021 Nov 16, 2021	BUY	$0.99 - $1.38 $29,700 - $41,400	30,000 Added 20.05%	179,627 $185,000
Q4 2020 Feb 16, 2021	BUY	$0.87 - $1.26 $43,500 - $63,000	50,000 Added 50.19%	149,627 $183,000
Q2 2020 Aug 14, 2020	SELL	$0.97 - $1.7 $86,938 - $152,365	-89,627 Closed	0 $0
Q1 2020 Jun 11, 2020	BUY	$0.9 - $1.95 $80,664 - $174,772	89,627 New	89,627 $99,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.